Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period...

Full description

Bibliographic Details
Main Authors: Marina Talamonti, Giovanna Malara, Ylenia Natalini, Federico Bardazzi, Andrea Conti, Andrea Chiricozzi, Cristina Mugheddu, Paolo Gisondi, Stefano Piaserico, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Anna Balato, Francesco Loconsole, Annamaria Offidani, Claudio Bonifati, Francesca Prignano, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2021-03-01
Series:Acta Dermato-Venereologica
Subjects:
anxiety
depression
psoriasis
secukinumab
quality of life
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3712

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3712

Similar Items